Letter to the EditorCharacterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase
References (8)
- et al.
Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome)
Blood
(2012) - et al.
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experience
Mayo Clin Proc
(2010) - et al.
Idiopathic systemic capillary leak syndrome (Clarkson disease)
J Allergy Clin Immunol
(2017) - et al.
Idiopathic and secondary capillary leak syndromes: a systematic review of the literature
Rev Med Interne
(2015)
Cited by (26)
Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors
2023, European Journal of CancerCitation Excerpt :Several reports describe recurrent pericardial or pleural drug-related effusions induced by ICPI, particularly in patients treated for thoracic cancer [8–16]. Some cases of immune-mediated polyserositis with severe generalised oedema related to ICPI have been occasionally previously reported [5,7,17,18], with the largest series comprising four cases, and some cases resembling with endothelial syndrome, such as SOS/VOD disease [5] or capillary leak syndrome (CLS) [17,19]. However, the clinical characteristics, frequency, severity, and outcome of patients with these immune-related generalised oedemas remain poorly known.
Immune checkpoint inhibitors-induced systemic capillary leak syndrome: A report of two cases
2023, Revue de Medecine InterneCitation Excerpt :Typically, patients develop transient edema and shock associated with a pathognomonic combination of hemoconcentration and hypoalbuminemia. SCLS can be either idiopathic (Clarkson's disease) or secondary to various causes including medications [1]. Herein, we report two cases of ICIs-associated SCLS and discuss key issues regarding its clinical presentation, pathophysiology, and treatment.
Anticancer Drug-Induced Capillary Leak Syndrome
2022, Kidney International ReportsCitation Excerpt :CLS is a rare18,19 but potentially lethal side effect of gemcitabine. It is the drug most often reported to be associated with CLS in the study by Mertz et al.14 The exact pathophysiology of gemcitabine-induced CLS is unclear.
Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome
2021, JACC: CardioOncologyCapillary leak syndrome: State of the art in 2021
2021, Revue de Medecine InterneUses of pharmacovigilance databases: An overview
2020, TherapiesCitation Excerpt :This study was able to describe relevant demographic and clinical data (sex predominence, median age at onset of DIL, time to onset) and profile changes over years of suspected drug-induced SLE reports with evolution of pharmacopeia [26]. A study with a similar design revealed a list of 52 suspected liable drugs at risk of inducing capillary syndrome [27]. These data might prove useful for clinicians when confronted to cases of suspected DIL and capillary leak syndrome.
This study is part of the Monitoring the IMmUological TOXicity of Drugs (MIMUTOX) research program registered under NCT03480529.
Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.